Tudor Investment Corp’s MoonLake Immunotherapeutics MLTX Stock Holding History

Tudor Investment Corp’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Sell	61,577 -41,939	-41%	-$695K	﹤0.01%	2265
2025 Q4	$1.36M	Buy	+103,516	New	+$1.22M	﹤0.01%	2073
2025 Q3	–	Sell	-31,714	Closed	-$1.65M	–	3683
2025 Q2	$1.5M	Buy	31,714 +122	+0.4%	+$4.97K	﹤0.01%	1865
2025 Q1	$1.23M	Buy	+31,592	New	+$1.36M	﹤0.01%	1678
2024 Q4	–	Sell	-31,840	Closed	-$1.61M	–	3337
2024 Q3	$1.61M	Buy	31,840 +4,667	+17%	+$219K	0.01%	1331
2024 Q2	$1.19M	Sell	27,173 -4,238	-13%	-$180K	0.01%	1363
2024 Q1	$1.58M	Buy	31,411 +1,257	+4%	+$68.2K	0.01%	1136
2023 Q4	$1.82M	Buy	30,154 +13,059	+76%	+$673K	0.01%	1143
2023 Q3	$974K	Buy	17,095 +3,546	+26%	+$196K	0.01%	1313
2023 Q2	$691K	Buy	+13,549	New	+$365K	0.01%	1528

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tudor Investment Corp's MLTX Position: Q1 2026 in Review

Tudor Investment Corp reduced its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q1 2026, selling an estimated $695K and leaving 61,577 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Tudor Investment Corp first reported a position in MLTX in Q2 2023 and has held it in 10 quarters since. The position peaked at $1.82M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Tudor Investment Corp held 61,577 shares of MoonLake Immunotherapeutics worth $1.15M as of Q1 2026.
Tudor Investment Corp sold 41,939 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $695K.
MoonLake Immunotherapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #2265 holding.
Tudor Investment Corp first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 10 quarters since.
Tudor Investment Corp's MoonLake Immunotherapeutics position peaked at $1.82M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.